Results of a phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).

被引：2
|
作者：
Fayad, Luis
Liebmann, James
Modiano, Manuel
Cohen, Gary
Pro, Barbara
Romaguera, Jorge
Stromatt, Scott
机构：
[1] MD Anderson Canc Ctr, Lymphoma Myeloma Dept, Houston, TX USA
[2] New Mexico Oncol Hematol Consultants, Albuquerque, NM USA
[3] Arizona Oncol Associates, Tucson, AZ USA
[4] Greater Baltimore Med Ctr, Ctr Canc, Baltimore, MD USA
[5] Cell Therapeut Inc, Clin Dev, Seattle, WA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2758.2758
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2758
引用
收藏
页码：781A / 781A
页数：1
相关论文
共 50 条
  • [1] Pixantrone Dimaleate in Combination With Fludarabine, Dexamethasone, and Rituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
    Srokowski, Tomasz P.
    Liebmann, James E.
    Modiano, Manuel R.
    Cohen, Gary I.
    Pro, Barbara
    Romaguera, Jorge E.
    Kuepfer, Christine
    Singer, Jack W.
    Fayad, Luis E.
    CANCER, 2011, 117 (22) : 5067 - 5073
  • [2] Preliminary results of a phase I/II trial of BBR-2778 (Pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Fayad, L
    Liebmann, J
    Modiano, M
    Cohen, GI
    Pro, B
    Romaguera, J
    Davite, C
    Lymboura, M
    Comis, S
    Laffranchi, BL
    BLOOD, 2004, 104 (11) : 373A - 373A
  • [3] Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
    Barr, Paul M.
    Fu, Pingfu
    Lazarus, Hillard M.
    Horvath, Nancy
    Gerson, Stanton L.
    Koc, Omer N.
    Bahlis, Nizar J.
    Snell, Michael R.
    Dowlati, Afshin
    Cooper, Brenda W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (01) : 89 - 96
  • [4] A phase I/II trial of pixantrone combined with fludarabine (FL), dexamethasone (DEX), and rituximab (FPD-R) for treatment of patients with recurrent indolent B-cell non-Hodgkin's lymphoma (NHL)
    Fayad, L
    Liebman, J
    Modiano, M
    Cohen, G
    Pro, B
    Romaguera, J
    Countouriotis, A
    Lymboura, M
    Comis, S
    Laffranchi, B
    ANNALS OF ONCOLOGY, 2005, 16 : 156 - 156
  • [5] Phase II results of bendamustine in combination with rituximab in relapsed indolent non-Hodgkin's lymphoma
    van der Jagt, Richard H.
    Cohen, Philip
    Cheson, Bruce D.
    Tulpule, Anil
    Herst, Jordan A.
    Lemieux, Bernard
    Schwartzberg, Lee S.
    Robinson, K. Sue
    Oliver, Jennifer W.
    Williams, Michael E.
    ANNALS OF ONCOLOGY, 2006, 17 : 200 - 200
  • [6] Comparative trial of BBR 2778 (pixantrone) plus rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Santoro, A.
    Voglova, J.
    Gabrail, N.
    Ciuleanu, T.
    Liberati, M.
    Hancock, B. W.
    Stromatt, S.
    Caballero, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 441S - 441S
  • [7] Phase I/II trial of clofarabine in refractory and/or relapsed non-Hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Bitran, J. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 243 - 243
  • [8] Phase I/II trial of clofarabine in refractory and/or relapsed non-hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Gozun, P.
    Bitran, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [10] A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma
    Bond, David A.
    Huang, Ying
    Christian, Beth A.
    Jaglowski, Samantha
    Benson, Don
    Alinari, Lapo
    Baiocchi, Robert A.
    Cohen, Jonathon B.
    Blum, Kristie A.
    Maddocks, Kami J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1750 - 1753
12345